Estrogen receptor-α-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant

Xinghua Long, Meiyun Fan, Kenneth P. Nephew

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Fulvestrant (ICI 182, 780) is a selective estrogen receptor downregulator (SERD) and potent antiestrogen. In estrogen receptor-alpha-positive ERα(+) breast cancer, the drug immobilizes ERα in the nuclear matrix, inducing receptor polyubiquitination and subsequent degradation via the 26s proteasome. We previously reported that fulvestrant-induced ERα degradation depends on the interaction of ERα with cytokeratins 8 and 18 (CK8/CK18). Here we further investigate the role of these two cytokeratins in the antagonistic activity of the SERD. Using ER-responsive reporter assays, we demonstrate greater antiestrogenic activity of fulvestrant in CK8/CK18(+) vs. CK8/CK18(-) cancer cells and loss of CK8/CK18 expression was observed in a breast cancer cell model for acquired fulvestrant resistance. In contrast, the presence of CK8/CK18 had no effect on the antiestrogenic activity of 4-hydroxytamoxifen, which was unable to induce an interaction between these CKs and ERα. By utilizing the ligand activity inversion ERα mutant L540Q to further examine the mechanism of fulvestrant action, we demonstrate that the ERα mutant does not interact with CK8/CK18 in the presence of fulvestrant and L540Q is not immobilized to the nuclear matrix after antiestrogen treatment. In transcription assays, fulvestrant displayed agonist activity, stimulating L540Q-mediated gene expression. In addition, fulvestrant did not induce an ERβ interaction with CK8/CK18 and subsequent ERβ degradation. Collectively, these results suggest that CK8/18 play an important role in the antiestrogenic action of fulvestrant in breast cancer cells and that these two cytokeratins could serve as prognostic markers for SERD therapy response in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)389-396
Number of pages8
JournalCancer Biology and Therapy
Volume9
Issue number5
DOIs
StatePublished - Mar 1 2010

Fingerprint

Keratins
Estrogen Receptors
Breast Neoplasms
Nuclear Matrix
Estrogen Receptor Modulators
fulvestrant
Keratin-8
Keratin-18
Estrogen Receptor alpha
Ligands
Gene Expression
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Estrogen receptor-α-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant. / Long, Xinghua; Fan, Meiyun; Nephew, Kenneth P.

In: Cancer Biology and Therapy, Vol. 9, No. 5, 01.03.2010, p. 389-396.

Research output: Contribution to journalArticle

@article{1252b908c30242838cc09eab941d7a21,
title = "Estrogen receptor-α-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant",
abstract = "Fulvestrant (ICI 182, 780) is a selective estrogen receptor downregulator (SERD) and potent antiestrogen. In estrogen receptor-alpha-positive ERα(+) breast cancer, the drug immobilizes ERα in the nuclear matrix, inducing receptor polyubiquitination and subsequent degradation via the 26s proteasome. We previously reported that fulvestrant-induced ERα degradation depends on the interaction of ERα with cytokeratins 8 and 18 (CK8/CK18). Here we further investigate the role of these two cytokeratins in the antagonistic activity of the SERD. Using ER-responsive reporter assays, we demonstrate greater antiestrogenic activity of fulvestrant in CK8/CK18(+) vs. CK8/CK18(-) cancer cells and loss of CK8/CK18 expression was observed in a breast cancer cell model for acquired fulvestrant resistance. In contrast, the presence of CK8/CK18 had no effect on the antiestrogenic activity of 4-hydroxytamoxifen, which was unable to induce an interaction between these CKs and ERα. By utilizing the ligand activity inversion ERα mutant L540Q to further examine the mechanism of fulvestrant action, we demonstrate that the ERα mutant does not interact with CK8/CK18 in the presence of fulvestrant and L540Q is not immobilized to the nuclear matrix after antiestrogen treatment. In transcription assays, fulvestrant displayed agonist activity, stimulating L540Q-mediated gene expression. In addition, fulvestrant did not induce an ERβ interaction with CK8/CK18 and subsequent ERβ degradation. Collectively, these results suggest that CK8/18 play an important role in the antiestrogenic action of fulvestrant in breast cancer cells and that these two cytokeratins could serve as prognostic markers for SERD therapy response in breast cancer patients.",
author = "Xinghua Long and Meiyun Fan and Nephew, {Kenneth P.}",
year = "2010",
month = "3",
day = "1",
doi = "10.4161/cbt.9.5.10926",
language = "English (US)",
volume = "9",
pages = "389--396",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Estrogen receptor-α-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant

AU - Long, Xinghua

AU - Fan, Meiyun

AU - Nephew, Kenneth P.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Fulvestrant (ICI 182, 780) is a selective estrogen receptor downregulator (SERD) and potent antiestrogen. In estrogen receptor-alpha-positive ERα(+) breast cancer, the drug immobilizes ERα in the nuclear matrix, inducing receptor polyubiquitination and subsequent degradation via the 26s proteasome. We previously reported that fulvestrant-induced ERα degradation depends on the interaction of ERα with cytokeratins 8 and 18 (CK8/CK18). Here we further investigate the role of these two cytokeratins in the antagonistic activity of the SERD. Using ER-responsive reporter assays, we demonstrate greater antiestrogenic activity of fulvestrant in CK8/CK18(+) vs. CK8/CK18(-) cancer cells and loss of CK8/CK18 expression was observed in a breast cancer cell model for acquired fulvestrant resistance. In contrast, the presence of CK8/CK18 had no effect on the antiestrogenic activity of 4-hydroxytamoxifen, which was unable to induce an interaction between these CKs and ERα. By utilizing the ligand activity inversion ERα mutant L540Q to further examine the mechanism of fulvestrant action, we demonstrate that the ERα mutant does not interact with CK8/CK18 in the presence of fulvestrant and L540Q is not immobilized to the nuclear matrix after antiestrogen treatment. In transcription assays, fulvestrant displayed agonist activity, stimulating L540Q-mediated gene expression. In addition, fulvestrant did not induce an ERβ interaction with CK8/CK18 and subsequent ERβ degradation. Collectively, these results suggest that CK8/18 play an important role in the antiestrogenic action of fulvestrant in breast cancer cells and that these two cytokeratins could serve as prognostic markers for SERD therapy response in breast cancer patients.

AB - Fulvestrant (ICI 182, 780) is a selective estrogen receptor downregulator (SERD) and potent antiestrogen. In estrogen receptor-alpha-positive ERα(+) breast cancer, the drug immobilizes ERα in the nuclear matrix, inducing receptor polyubiquitination and subsequent degradation via the 26s proteasome. We previously reported that fulvestrant-induced ERα degradation depends on the interaction of ERα with cytokeratins 8 and 18 (CK8/CK18). Here we further investigate the role of these two cytokeratins in the antagonistic activity of the SERD. Using ER-responsive reporter assays, we demonstrate greater antiestrogenic activity of fulvestrant in CK8/CK18(+) vs. CK8/CK18(-) cancer cells and loss of CK8/CK18 expression was observed in a breast cancer cell model for acquired fulvestrant resistance. In contrast, the presence of CK8/CK18 had no effect on the antiestrogenic activity of 4-hydroxytamoxifen, which was unable to induce an interaction between these CKs and ERα. By utilizing the ligand activity inversion ERα mutant L540Q to further examine the mechanism of fulvestrant action, we demonstrate that the ERα mutant does not interact with CK8/CK18 in the presence of fulvestrant and L540Q is not immobilized to the nuclear matrix after antiestrogen treatment. In transcription assays, fulvestrant displayed agonist activity, stimulating L540Q-mediated gene expression. In addition, fulvestrant did not induce an ERβ interaction with CK8/CK18 and subsequent ERβ degradation. Collectively, these results suggest that CK8/18 play an important role in the antiestrogenic action of fulvestrant in breast cancer cells and that these two cytokeratins could serve as prognostic markers for SERD therapy response in breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=77953706542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953706542&partnerID=8YFLogxK

U2 - 10.4161/cbt.9.5.10926

DO - 10.4161/cbt.9.5.10926

M3 - Article

VL - 9

SP - 389

EP - 396

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 5

ER -